Salarius Pharmaceuticals, Inc.
SLRX
$3.20
-$0.42-11.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -48.32% | 25.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -43.82% | 15.45% | |||
| Operating Income | 43.82% | -15.45% | |||
| Income Before Tax | 43.97% | -16.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 43.97% | -16.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.97% | -16.78% | |||
| EBIT | 43.82% | -15.45% | |||
| EBITDA | 43.85% | -15.46% | |||
| EPS Basic | -- | -- | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | -- | -- | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | -- | -- | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||